Trials / Completed
CompletedNCT00041483
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 530 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anecortave Acetate 15 mg sterile suspension | |
| OTHER | Photodynamic Therapy (PDT) |
Timeline
- Start date
- 2002-06-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2002-08-01
- Last updated
- 2014-07-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00041483. Inclusion in this directory is not an endorsement.